(Q34650456)

3 August 2017

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation (English)

1 reference

3 August 2017

J Killestein

1

1 reference

3 August 2017

A Vennegoor

2

1 reference

3 August 2017

A E L van Golde

3

1 reference

3 August 2017

R L J H Bourez

4

1 reference

3 August 2017

M L B Wijlens

5

1 reference

3 August 2017

M P Wattjes

6

1 reference

3 August 2017

23 November 2014

1 reference

Case Reports in Neurological Medicine

3 August 2017

1 reference

3 August 2017

2014

1 reference

3 August 2017

307872

1 reference

Creative Commons Attribution 3.0 Unported

3 August 2017

start time

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

Fingolimod after natalizumab and the risk of short-term relapse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

Progressive multifocal leukoencephalopathy after natalizumab discontinuation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

Tumefactive MS lesions under fingolimod: a case report and literature review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258922

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

7 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F307872

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F307872

Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F307872

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F307872

Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25506447

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25506447

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25506447

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2014/307872

1 reference

3 August 2017

1 reference

3 August 2017

1 reference